ASCO 2023 | Claudin 18.2: a biomarker for gastric cancer

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the importance of the claudin 18.2 biomarker in gastric cancer. claudin 18.2 is a tight junction protein that is usually expressed in healthy apical gastric mucosal cells. When these cells become malignant, their membranes become exposed, thus allowing them to be targeted. The novel antibody, zolbetuximab, targets claudin 18.2 and has been evaluated in randomized Phase III trials. SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) have exhibited enhanced progression-free survival (PFS) and overall-survival (OS) for the combination of zolbetuximab with first-line chemotherapy in claudin 18.2 positive gastric cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.